We are live on ! Find out more

OptimizeRx

OPRX

Market cap $156M

8.28 USD

-0.10

1.19%

At close Updated Oct 9, 4:00 PM EDT

1 day

-1.19%

5 days

-3.72%

1 month

15.48%

3 months

31.85%

6 months

34.42%

Year to date

-33.33%

1 year

-54.73%

5 years

-89.79%

10 years

-20.38%

About: OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.

Employees: 105

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making OptimizeRx's authenticated point of care inventory available directly to advertisers using The Trade Desk's leading, data-driven demand side platform (DSP).

OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath

OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook

OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-margin offerings. OPRX reaffirmed 2026 guidance: revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.

OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook

OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence

New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow

OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence

OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced that management will participate in the 10th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 10, 2026, in New York, NY.

OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Troy Sarich as a Company advisor.

OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor

OptimizeRx Q2 Earnings Call Highlights

OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.

OptimizeRx Q2 Earnings Call Highlights

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

Zacks Investment Research

OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago.

OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates

OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth

The Company Names Andy D'Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027

OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth

OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

– Q2 revenue totals $20.5 million– Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively– Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million– Completed debt refinancing with $35 million traditional banking facility, including $25 million term loan and $10 million undrawn revolver; repaid $8.3 million of principal since inception

OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

See News Rankings

Price charts implemented using Lightweight Charts™